Document Detail


Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases.
MedLine Citation:
PMID:  11576943     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Skeletal resistance to parathyroid hormone (PTH) was suggested initially as a mechanism of PTH hypersecretion in uremia. Because of the effective suppression of PTH by recently developed therapeutic modalities, this background abnormality has been uncovered and currently recognized as relative hypoparathyroidism in terms of its relation to bone turnover. Thus, PTH levels two to three times greater than normal are usually required to keep bone turnover normal in uremia. Recent studies suggested that PTH activity may be overestimated using the conventional intact PTH assay. In addition, several steps to osteoclastogenesis are suspected to be disturbed in uremia. Additional studies at cellular and molecular levels are needed to establish preventive and therapeutic modalities for this abnormality.
Authors:
M Fukagawa; J J Kazama; T Shigematsu
Related Documents :
17991723 - Life-long caloric restriction reveals biphasic and dimorphic effects on bone metabolism...
20826233 - Effects of strontium in modified biomaterials.
11153463 - Mechanical analysis of the healing of different osteotomies fixed externally.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  38     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-09-28     Completed Date:  2001-12-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S152-5     Citation Subset:  IM    
Affiliation:
Division of Nephrology and Dialysis Center, Kobe University School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. fukagawa@med.kobe-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bone Resorption / etiology,  metabolism*
Bone and Bones / metabolism*
Disease Progression
Glycoproteins / metabolism
Humans
Hyperplasia
Osteoprotegerin
Parathyroid Glands / metabolism,  pathology
Parathyroid Hormone / metabolism*
Receptors, Cytoplasmic and Nuclear / metabolism
Receptors, Tumor Necrosis Factor
Uremia / complications,  metabolism*
Chemical
Reg. No./Substance:
0/Glycoproteins; 0/Osteoprotegerin; 0/Parathyroid Hormone; 0/Receptors, Cytoplasmic and Nuclear; 0/Receptors, Tumor Necrosis Factor; 0/TNFRSF11B protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients.
Next Document:  Osteoclastogenesis and osteoclast activation in dialysis-related amyloid osteopathy.